Kura Oncology's Upcoming Q2 2025 Financial Results Report

Kura Oncology's Upcoming Financial Results Announcement

Kura Oncology, Inc. (Nasdaq: KURA), a pioneering biopharmaceutical company focused on precision medicines for cancer treatment, is gearing up to report its second quarter financial results. The announcement is scheduled to take place after the close of U.S. financial markets on a Thursday in early August. Following the report release, Kura’s management will host a comprehensive webcast and conference call to discuss the results and provide essential insights into the company’s progress.

Details of the Webcast and Conference Call

The live conference call will commence at 4:30 p.m. Eastern Time (ET), which is 1:30 p.m. Pacific Time (PT). Interested participants can join the call by dialing the appropriate phone numbers: (800) 579-2543 for U.S. callers and (785) 424-1789 for international participants. When prompted, attendees will need to enter the conference ID: KURAQ2. If you miss the live session, a recording will be accessible through Kura's investor relations page, allowing stakeholders to stay updated on the developments.

Company Overview of Kura Oncology

Kura Oncology is devoted to the advancement of precision cancer medicines, with its pipeline highlighting innovative small molecule therapy candidates. A significant part of its portfolio includes Ziftomenib, which is recognized as the first investigational treatment to obtain Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for acute myeloid leukemia (AML) characterized by relapsed or refractory NPM1 mutations. This designation underlines the therapy's potential and the company's commitment to addressing urgent medical needs in oncology.

Key Partnerships and Collaborations

In a promising move for its future, Kura has established a global strategic collaboration agreement with Kyowa Kirin, targeting the development and commercialization of Ziftomenib for AML and other related malignancies. This partnership aims to facilitate rapid progress in clinical trials and the expansion of treatment options for patients suffering from these conditions.

Clinical Trials and Developments

The companies involved in this collaboration have recently completed enrollment in KOMET-001, a Phase 2 trial aimed at evaluating Ziftomenib in relapsed or refractory NPM1-m AML. Excitingly, in the second quarter of 2025, they announced that the FDA accepted a New Drug Application for Ziftomenib, promising to streamline the path towards making this vital therapy available for adult patients. The anticipated target action date for the Prescription Drug User Fee Act is set for late November 2025, showcasing positive momentum ahead.

Innovative Drug Candidates in Development

Meanwhile, Kura's research is not limited to Ziftomenib alone. The company is actively conducting clinical trials for other promising drug candidates. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is currently under evaluation in a Phase 1 dose-escalation trial as both monotherapy and in combination with targeted therapies for various solid tumors. In addition, Tipifarnib, another potent FTI, is undergoing a Phase 1/2 trial in combination with a targeted drug for patients with PIK3CA-dependent head and neck squamous cell carcinoma.

Connection with Investors and Media

For investors and media inquiries, Kura Oncology maintains open lines of communication through their investor relations team. Contact Greg Mann at 858-987-4046 for any questions or further information regarding the company’s financial disclosures or upcoming events.

Frequently Asked Questions

What is Kura Oncology's primary focus?

Kura Oncology is primarily focused on developing precision medicines for the treatment of cancer, utilizing innovative small molecule drug candidates.

When will Kura Oncology report its Q2 2025 financial results?

Kura Oncology is scheduled to report its second quarter financial results on a Thursday in early August 2025.

How can I access the conference call?

The conference call can be accessed by calling (800) 579-2543 for domestic callers and (785) 424-1789 for international participants. The conference ID is KURAQ2.

What recognition has Ziftomenib received from the FDA?

Ziftomenib has received Breakthrough Therapy Designation from the FDA, indicating its potential to address significant unmet medical needs in AML.

Who can I contact for media inquiries?

For media inquiries, you can reach out to Greg Mann at 858-987-4046.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.